Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
0.73(c) 0.72(c) 0.75(c) 0.74(c) 0.75 Last
299 021 207 872 6 193 722 692 287 236 248 Volume
+4.29% -1.37% +4.17% -1.33% +1.35% Change
More quotes
Financials (€)
Sales 2016 0,74 M
EBIT 2016 -12,5 M
Net income 2016 -10,4 M
Debt 2016 1,47 M
Yield 2016 -
Sales 2017 -
EBIT 2017 0,56 M
Net income 2017 -10,5 M
Finance 2017 13,5 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 2,15
EV / Sales2016 44,9x
EV / Sales2017 0
Capitalization 31,8 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis, and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
12/08 NEOVACS : obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE..
12/08 NEOVACS : obtains FDA Fast Track designation for IFN Kinoid in Lupus (SLE)
12/07 NEOVACS : obtains FDA “Fast Track” designation for IFNa Kinoid in Lu..
12/07 DGAP-NEWS : Neovacs obtains FDA 'Fast Track' designation for IFNα Kinoid i..
12/07 NEOVACS : obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE..
11/23 DGAP-NEWS : Neovacs signs production partnership with 3P Biopharmaceuticals, a l..
11/23 NEOVACS : signs production partnership with 3P Biopharmaceuticals, a leading GMP..
11/16 NEOVACS : Acquires Interferon Alpha Manufacturing Technology From AMEGABIOTECH
11/15 DGAP-NEWS : Neovacs acquires interferon alpha manufacturing technology from ameg..
11/15 NEOVACS : acquires interferon alpha manufacturing technology from AMEGABIOTECH
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,70 €
Spread / Average Target 130%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-31.92%34
INCYTE CORPORATION-5.14%19 381
QUINTILES IMS HOLDINGS..12.93%19 089
CELLTRION, INC.--.--%9 846
SEATTLE GENETICS, INC.49.13%9 474
LONZA GROUP AG9.44%9 150
More Results